ERAS - Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
2024-05-20 01:30:00 ET
Summary
- Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments.
- Zai Lab reported China’s NMPA approved Augtyro (repotrectinib) as a treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
- Beijing InnoCare Pharma has completed the enrollment process in a China Phase II trial of ICP-488, a potential psoriasis therapy.
Deals and Financings
Japan’s Takeda ( TAK , TKPHF ; TSE: 4502) acquired global rights to an Alzheimer’s therapy developed by AC Immune SA ( ACIU ) of Switzerland for $100 million upfront and up to $2.1 billion in milestone payments (see story ). With the $100 million, Takeda owns an option to license AC Immune’s active immunotherapies that target toxic forms of amyloid beta (Abeta), including ACI-24.060. ACI-24.060 is an anti-Abeta active immunotherapy candidate aimed at reducing the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. Currently, ACI-24.060 is being tested in a double-blind, placebo-controlled Phase Ib/II trial in subjects with mild Alzheimer’s disease and in adults with Down's syndrome....
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal